



CIN NO.: L24230WB1982PLC034492

Date: 14th November, 2019

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

Dear Sir,

Sub: Outcome of Board Meeting held on 14th November, 2019.

This is to inform you that, Pursuant to Regulation 30 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Director at its meeting was held its Registered Office on Thursday, 14th November, 2019 (**commenced at 11:30 A.M. and concluded at 12:35 P.M.**) have inter-alia considered, approved and adopted the following agenda:

1. Standalone Unaudited Financial Results and Financial Statements of the Company for the quarter and half year ended 30th September, 2019 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
2. Limited Review Report by the Statutory Auditors on Standalone Unaudited Financial Results for 02nd quarter ended 30th September, 2019

This information is also available on Company's website: www.adinathbio.com and on the stock exchange website: www.cse-india.com.


The Company would be publishing Extract of Un-Audited Financial Result for the Quarter ended 30-09-2019, in accordance with Regulation 47(1) (b) of the Listing Regulation.

Please acknowledge the receipt.

Thanking you,
Yours faithfully,

For Adinath Bio-Labs Limited

Kishan Singh
(Whole-Time Director)
(DIN: 07526266)




Encl.: As above.

Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2019							
Sr. No.	Particulars	PART I					(Amount in Rs.)
		Quarter Ended			Half Year Ended		Year Ended
		Unaudited (30/09/2019)	Unaudited (30/06/2019)	Unaudited (30/09/2018)	Unaudited (30/09/2019)	Unaudited (30/09/2018)	Audited (31/03/2019)
1	Income from operations						
	(a) Net Sales / income from operations	-	-	-	-	-	-
	(b) Other Income	63,596	62,904	71,218	1,26,500	96,542	2,61,744
	Total income from operations (net)	63,596	62,904	71,218	1,26,500	96,542	2,61,744
2	Expenses						
	(a) Changes in inventories of finished goods, work-in-progress and stock- in-trade	-	-	-	-	-	-
	(b) Employee benefits expense	1,14,783	1,42,233	73,476	2,57,016	1,33,476	3,14,643
	(c) Finance Cost	-	-	-	-	-	-
	(d) Depreciation and amortisation expense	13,394	13,394	25,632	26,788	52,519	1,02,996
	(e) Other expenses	1,17,801	2,61,068	1,32,661	3,78,869	26,73,691	51,98,137
	Total expenses	2,45,978	4,16,695	2,31,769	6,62,673	28,59,686	56,15,776
3	Profit / (Loss) from operations before Exceptional & Extraordinary Items (1-2)	(1,82,382)	(3,53,791)	(1,60,551)	(5,36,173)	(27,63,144)	(53,54,032)
4	Exceptional & Extraordinary Items	134,72,226	60,25,000	-	194,97,226	-	198,80,000
5	Profit / (Loss) before Tax (3 ± 4)	(136,54,608)	(63,78,791)	(1,60,551)	(200,33,399)	(27,63,144)	(252,34,032)
6	Tax expense						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	(1,76,016)
	Earlier Years	-	-	-	-	-	-
	Total Tax Expenses	-	-	-	-	-	(1,76,016)
7	Net Profit/(Loss) after tax(5 ± 6)	(136,54,608)	(63,78,791)	(1,60,551)	(200,33,399)	(27,63,144)	(250,58,016)
8	Other Comprehensive Income / (Loss)						
9	Total Comprehensive Income / (Loss) (7 ± 8)	(136,54,608)	(63,78,791)	(1,60,551)	(200,33,399)	(27,63,144)	(250,58,016)
10	Paid-up equity share capital (Face Value in Re.)	2207,42,560	2207,42,560	2207,42,560	2207,42,560	2207,42,560	2207,42,560
11	Earnings Per Share (Not annulled except for year ended)						
	Basic & Diluted	(0.06)	(0.03)	(0.00)	(0.09)	(0.01)	(0.11)

Statement of Assets and Liabilities as on 30th September, 2019

Sl. No.	Particulars	(Amount in Rs.)	
		As at 30th September, 2019 Unaudited	As at 31st March, 2019 Audited
I	ASSETS		
A	Non-current assets		
	a) Property, plant and equipment	1,97,554	2,24,342
	b) Financial assets		
	i) Investments	2,87,500	2,87,500
	ii) Other Non current financial assets	407,08,050	581,75,694
	Total Non-current assets	411,93,104	586,87,536
B	Current assets		
	a) Financial assets		
	i) Trade Receivables	40,14,221	40,14,221
	ii) Cash and cash equivalents	3,43,709	2,38,807
	iii) Loans	25,30,000	25,30,000
	iv) Other current financial assets	13,80,377	41,20,343
	Total Current assets	82,68,307	109,03,371
	TOTAL ASSETS	494,61,411	695,90,907
II	EQUITY AND LIABILITIES		
A	EQUITY		
	a) Equity Share capital	2207,42,560	2207,42,560
	b) Other Equity	(1797,73,762)	(1597,40,363)
	Total equity	409,68,798	610,02,197
B	LIABILITIES		
I	Non-current liabilities		
	(a) Deferred tax liabilities (net)	-	-
	Total Non-current liabilities	-	-
II	Current liabilities		
	a) Financial liabilities	-	-
	b) Other current liabilities	45,298	1,41,395
	c) Current tax liabilities	84,47,315	84,47,315
	Total Current liabilities	84,92,613	85,88,710
	TOTAL EQUITY AND LIABILITIES	494,61,411	695,90,907

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2019			
(Amount in Rs.)			
	Particulars	For the Half Year Ended 30th September, 2019	For the Year Ended 31st March, 2019
(A)	Cash Flow From Operating Activities		
	Net Profit before Tax & Exceptional items	(5,36,173)	(53,54,032)
	Adjustments for ::-		
	Provision for diminution in value of investments	-	37,503
	Provision for doubtful debts	-	21,90,048
	Fixed Assets Written off	-	22,76,767
	Other Income	(1,26,500)	(2,52,000)
	Depreciation and Amortisation on tangible assets	26,788	1,02,996
	Operating Profit Before Working Capital Changes	(6,35,885)	(9,98,718)
	Adjustments for ::-		
	Working/ Operating Capital Changes		
	(Increase)/ Decrease in Other Receivables	7,10,384	15,36,017
	Increase/ (Decrease) in Other Current Liabilities	(96,097)	(6,33,817)
	Cash Generated From Operations	(21,598)	(96,518)
	Payment of Taxes	-	-
	Net Cash Flow (Used in)/ Generated From Operating Activities (A)	(21,598)	(96,518)
(B)	Cash Flow From Investing Activities		
	Receipt/ (Repayment) of loan and advances	-	(10,000)
	Interest (Net)	1,26,500	2,52,000
	Net Cash Flow (Used in)/ Generated From Investing Activities (B)	1,26,500	2,42,000
(C)	Cash Flow From Financing Activities	-	-
	Net Cash Flow (Used in)/ Generated From Financing Activities (C)	-	-
	Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C)	1,04,902	1,45,482
	Cash & Cash Equivalents as at the beginning of the year	2,38,807	93,325
	Cash & Cash Equivalents as at the end of the year	3,43,709	2,38,807



Notes:

- 1 The above Unaudited Financial results have been reviewed by the Audit committee at their meeting held on 14th November, 2019 and adopted by the Board of Directors at their meeting held on 14th November, 2019.
- 2 The results are based on the financial statements prepared by the Company's management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- 3 The company is engaged in the business of Trading and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- 4 The Statutory Auditors of the Company have conducted a limited review of the above unaudited standalone financial results of the Company for the quarter and half year ended September 30, 2019 and issued an unqualified report in this behalf.
- 5 Provisions for income tax and deferred tax will be made at the end of the year except for those which pertains to earlier years on account of any specific order received by the company.
- 6 The accumulated losses have eroded net worth to the extent of 50% of the capital of the Company.
- 7 An amount of Rs.134.72 lacs have been provided and charged to profit and loss account under exceptional items on account of provision for doubtful receivables for the quarter ended 30th September, 2019.
- 8 Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

**By order of the Board
For Adinath Bio-Labs Limited**



Kishan Singh
Kishan Singh
Whole Time Director
DIN :07526266

Date: 14th November, 2019

Place: Kolkata

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Adinath Bio-Labs Limited


We have reviewed the accompanying statement of unaudited financial results of **M/s. Adinath Bio-Labs Limited** (the "Company") for the quarter and half year ended on 30th September, 2019 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KSA & Co.
Chartered Accountants
FRN: 003822C


Kamal Piyush
Partner

Membership No.: 083399

Place: Kolkata

Date: 14/11/2019

UDIN: 19083399AAAAIX9573

K-8, Ground Floor, Jangpura Extension, New Delhi-110014
Ph.: +91 11 24323155, +91 11 43553157, Mobile: 9811061238
Email: kamalpiyush@ksaindia.in, ksaindia@ksaindia.in, Website: www.ksaindia.in
Offices at Mumbai, Kolkata, Surat, Bhubaneshwar, Gurgaon